Does your PGx detection method have blind spots?
CYP2D6 is responsible for the metabolism and elimination of approximately 25% of clinically used medications. Depending on ethnicity, up to 37% of individuals possess a non-functional CYP2D6 hybrid allele. Common CYP2D6 genotyping and copy number detection methods cannot detect these alleles, resulting in pharmacogenetic profile mischaracterization. Dr. Houda Hachad will offer recommendations for overcoming this challenge to achieve a comprehensive CYP2D6 profile and more accurate PGx results.
Questions That Will Be Answered:
- What is a CYP2D6 hybrid allele?
- How prevalent are CYP2D6 hybrid alleles across populations?
- How does missing them affect PGx results?
- What can be done to ensure accurate CYP2D6 characterization?
Dr. Houda Hachad
Pharm. D, Chief Scientific Officer
Translational Software, Bellevue, Washington
Houda is an entrepreneurial scientist with deep experience in pharmacology and pharmacogenetics. At the University of Washington, she co-developed two knowledge-based technologies, a drug interaction database (DIDB) and a pharmacogenetics database (e-PKGene©). Both leverage revenue-based funding and are widely used by pharmaceutical companies, regulatory agencies, and academic institutions worldwide.